Catalogo dei prodotti della ricerca

MILLEFIORINI, Enrico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.327
AS - Asia 1.849
EU - Europa 1.383
SA - Sud America 322
AF - Africa 76
OC - Oceania 5
Totale 7.962
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.263
SG - Singapore 832
IT - Italia 406
CN - Cina 318
HK - Hong Kong 286
BR - Brasile 239
IN - India 205
DE - Germania 197
SE - Svezia 193
FI - Finlandia 156
UA - Ucraina 133
RU - Federazione Russa 103
VN - Vietnam 69
GB - Regno Unito 47
AR - Argentina 36
CA - Canada 36
BG - Bulgaria 25
FR - Francia 24
CI - Costa d'Avorio 21
ID - Indonesia 18
JP - Giappone 18
BD - Bangladesh 17
IE - Irlanda 17
IQ - Iraq 17
MX - Messico 16
MA - Marocco 15
TR - Turchia 14
ZA - Sudafrica 13
RO - Romania 12
AT - Austria 10
BE - Belgio 10
EC - Ecuador 10
VE - Venezuela 10
CZ - Repubblica Ceca 8
NL - Olanda 8
SA - Arabia Saudita 8
CL - Cile 7
PL - Polonia 7
UY - Uruguay 7
UZ - Uzbekistan 7
AU - Australia 5
CO - Colombia 5
ES - Italia 5
IL - Israele 5
LT - Lituania 5
DZ - Algeria 4
EG - Egitto 4
IR - Iran 4
KE - Kenya 4
MY - Malesia 4
PY - Paraguay 4
TG - Togo 4
CH - Svizzera 3
ET - Etiopia 3
JO - Giordania 3
KZ - Kazakistan 3
MK - Macedonia 3
NP - Nepal 3
PA - Panama 3
RS - Serbia 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BO - Bolivia 2
GR - Grecia 2
HN - Honduras 2
JM - Giamaica 2
OM - Oman 2
PK - Pakistan 2
QA - Qatar 2
SN - Senegal 2
TN - Tunisia 2
AD - Andorra 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
CG - Congo 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GD - Grenada 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
GY - Guiana 1
KG - Kirghizistan 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
NG - Nigeria 1
PE - Perù 1
PH - Filippine 1
SC - Seychelles 1
SV - El Salvador 1
TW - Taiwan 1
Totale 7.962
Salva come PNG Salva come JPEG
Città #
Fairfield 609
Singapore 478
Ashburn 421
Woodbridge 355
Hong Kong 283
Seattle 231
Chandler 230
Houston 211
Wilmington 200
Cambridge 190
Ann Arbor 145
Rome 134
Princeton 117
Beijing 91
Plano 85
Dearborn 79
San Paolo di Civitate 73
Santa Clara 73
Dallas 70
Los Angeles 67
Lawrence 60
Boston 57
Buffalo 50
Des Moines 50
Munich 50
Helsinki 49
Jacksonville 48
San Diego 41
Frankfurt am Main 30
Norwalk 30
Cosenza 29
São Paulo 27
Andover 26
Ho Chi Minh City 25
Millbury 25
New York 25
Sofia 25
Turku 25
Moscow 24
Hillsboro 22
Abidjan 21
Hanoi 21
Redondo Beach 21
Federal 17
Boardman 16
Dublin 16
Toronto 16
Milan 15
Tokyo 14
Casablanca 13
Falls Church 12
Fasano 12
Jakarta 11
Brussels 10
Columbus 10
Nuremberg 10
Bühl 9
Chicago 9
Hefei 9
Baghdad 8
Nanjing 8
Bari 7
Fremont 7
Grafing 7
London 7
Mexico City 7
Phoenix 7
Rio de Janeiro 7
Brasília 6
Brno 6
Changsha 6
Falkenstein 6
Montevideo 6
Ottawa 6
Shanghai 6
Tashkent 6
Zhengzhou 6
Atlanta 5
Auburn Hills 5
Clementon 5
Guangzhou 5
Indiana 5
Johannesburg 5
San Mateo 5
The Dalles 5
Warsaw 5
Bengaluru 4
Chennai 4
Council Bluffs 4
Dhaka 4
Guarulhos 4
Guayaquil 4
Jinan 4
Kuala Lumpur 4
Lappeenranta 4
Lomé 4
Mannheim 4
Maracaibo 4
Montreal 4
Nairobi 4
Totale 5.342
Salva come PNG Salva come JPEG
Nome #
Deep grey matter involvement and altered sensory gating in multiple sclerosis 181
A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis 176
Trigeminal neuralgia and pain related to multiple sclerosis. 158
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 141
La neurologia della Sapienza 135
Increased circulating levels of vitamin D binding protein in MS patients 133
Mechanisms of pain in multiple sclerosis: A combined clinical and neurophysiological study 132
BETA2-MICROGLOBULIN SERUM LEVEL IS NOT A MARKER OF DISEASE ACTIVITY IN MULTIPLE SCLEROSIS 131
Fingolimod vs dimethyl fumarate in multiple sclerosis. a real-world propensity score-matched study 129
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study 129
Computerized color perimetry in multiple sclerosis 127
Altered sensorimotor integration in multiple sclerosis: A combined neurophysiological and functional MRI study 127
A controlled study of potential risk factors preceding exacerbation in multiple sclerosis. 124
Expression of biomarkers of interferon type I in patients suffering from chronic diseases 121
Lead poisoning during heroin addiction 120
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 119
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis. An Italian, Multicenter, Real-World Study 119
Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation 118
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis 117
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 116
Depression in the early phase of MS: influence of functional disability, cognitive impairment and brain abnormalities. 116
Involvement of the limbic system in multiple sclerosis patients with depressive disorders 110
Photophobia in multiple sclerosis 109
Cortical M1 plasticity and metaplasticity in patients with multiple sclerosis 109
Campimetria cromatica nella sclerosi multipla 108
Mitochondrial Genome Profile in Demyelinating Diseases 108
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 106
Anterior corpus callosum atrophy and verbal fluency in multiple sclerosis. 105
Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. 102
Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers 101
Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis - Results of the BetaPlus observational cohort study 101
Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases 99
Cardiac autonomic dysfunction in relapsing-remitting multiple sclerosis during a stable phase 99
Circadian variation in the onset of acute cerebral ischemia: ethiopathogenetic correlates in 80 patients given angiography. 98
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. 96
Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study 96
Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. 93
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 92
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment 90
An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis 90
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. 89
Effect of stress on cardiovascular regulation in neurological diseases with dysautonomia. 85
A one-year study on the pharmacodynamic profile of interferon-beta1a in MS 85
Involvement of the limbic system in multiple sclerosis patients with depressive disorders. 85
Brain atrophy in relasping-remitting multiple sclerosis:relationship with "black holes", disease duration and disability 82
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by rebiject autoinjection over a 1-year period: The CoSa study 79
Fatigue in MS is associated with specific clinical features. 78
Influenza immunization in multiple sclerosis 78
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 77
Interferon beta-1a in relapsing-remitting multiple sclerosis:effect on hypointense lesion volume on T1-weighted images 76
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. 76
INVASIVE TREATMENT OF ACUTE STROKE 75
Duloxetine for the Treatment of Overactive Bladder Syndrome in Multiple Sclerosis: A Pilot Study 73
Invasive treatment of acute stroke. 72
ccl2 induction by 1,25 (oh)2d3 in debdritic cells from healty donors and ms patients 72
Detection of human herpesviruses and polyomaviruses DNA in a group of patients with relapsing-remitting multiple sclerosis 72
Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. 72
the prevalence of ms in central italy 71
Fast spin-echo and fast fluid-attenuated inversion-recovery versus conventional spin-echo sequences for MR quantification of multiple sclerosis lesions. 70
Proteolytic balance in patients with multiple sclerosis during interferon treatment 70
The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. 67
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. 66
FATIGUE IN MS IS ASSOCIATED WITH SPECIFIC CLINICAL-FEATURES 66
Fattori prognostici in pazienti con sclerosi multipla di tipo recidivante-remittente. Studio longitudinale di 3 anni. 64
A longitudinal study in multiple sclerosis 63
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. 63
Subclinical peripheral nervous system involvement in multiple sclerosis 61
Fast spin-echo and fast fluid-attenuated inversion-recovery versus conventional spin-echo sequences for MR quantification of multiple sclerosis lesions. 61
Lack of association between macrocytosis and multiple sclerosis. 61
null 60
Sclerosi Multipla 59
Evolution and severity markers in 233 MS patients. 59
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis 58
Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. 57
null 57
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients 56
Controlled clinical trials in stroke. 56
Somatosensory temporal discrimination threshold is impaired in patients with multiple sclerosis 56
Possibile ruolo delle infezioni virali nell’eziopatogenesi della sclerosi multipla: indagine su un gruppo di pazienti con SM remittente 53
Prognostic indicators in pediatric clinically isolated syndrome 52
null 49
null 49
short-term brain atrophy changes in r-r multiple sclerosis 48
Viral infections and multiple sclerosis: research on remittent-relapsing MS patients. 47
null 45
The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis 45
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 44
Opposite regulatory effects of IFN-β and IL-3 on C-type lectin receptors, antigen uptake, and phagocytosis in human macrophages 41
Subclinical peripheral nervous system involvement in multiple sclerosis. 40
Intradetrusorial botulinum toxin in patients with multiple sclerosis: A neurophysiological study 40
Prognosi precoce nella paralisi di Bell in base a rilievi clinico neurofisiologici standardizzati 36
null 33
Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. 32
Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. 32
Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations. 31
Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations. 31
the global adherence project a multicenter observation study on adherence to disease-modifying therapies in patients with rr-ma. 29
natalizumab therapy of ms study group 27
OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results 26
The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis 8
Totale 8.146
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.163
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.163
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021294 0 0 0 0 4 29 33 42 41 97 38 10
2021/20221.002 6 58 77 45 143 42 26 101 70 79 166 189
2022/2023978 219 197 49 74 93 117 31 45 99 5 40 9
2023/2024427 20 54 17 24 36 53 19 40 2 52 52 58
2024/20251.692 59 84 67 47 91 103 106 76 276 159 136 488
2025/20261.309 355 150 294 294 216 0 0 0 0 0 0 0
Totale 8.151